Wednesday 18 November 2026Search
World

FDA approves first drug shown to help infantile-onset NPC patients live longer

2 min read

The Food and Drug Administration on Tuesday 17 November 2026 approved Lembaz (adrabetadex) injection, the first treatment shown to help people with infantile-onset Niemann-Pick disease type C live longer. Lembaz is approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6.

Acting FDA Commissioner Kyle Diamantas said the approval marks an important milestone for families living with Niemann-Pick disease type C. He said it is the first time there is a treatment shown to help adults and children with the serious disease live longer, and that the agency is committed to continuing to support the development of therapies for the rare disease community.

Niemann-Pick disease type C is a rare, inherited lysosomal storage disorder affecting an estimated 1 in 150,000 people, in which the body cannot properly process cholesterol and other fats inside cells. Over time these substances accumulate, particularly in the brain, causing progressive neurological decline, including loss of movement, coordination, and the ability to swallow. Patients whose neurological symptoms begin before age 6 face the most serious form of the disease.

Before this approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death. Both carry age and weight restrictions that limit access for the youngest and most seriously affected patients. A trained healthcare provider gives Lembaz as an injection directly into the spinal canal, a procedure called an intrathecal injection, every two weeks.

To assess whether Lembaz reduced the risk of death, the FDA examined the survival of 36 patients treated with Lembaz across three clinical studies and an expanded access program. All patients had neurological manifestations of NPC that occurred prior to age 6. Treated patients had longer overall survival than the matched external control group, with a 55% reduction in the risk of death. The median survival time was 8.5 years for the treated group compared with 4.9 years in the control group. The survival benefit was observed regardless of whether patients were also taking miglustat.

The most common side effects of Lembaz include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss. The agency said a comprehensive hearing evaluation should be performed on patients before starting Lembaz and regularly throughout treatment, and dose adjustments may be needed based on the results of these evaluations.

Lembaz received Breakthrough Therapy designation. The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.